Andrew William McPherson

Dr. Andrew William McPherson

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PBPaul C. Boutros
Paul C. Boutros
MFMichael Fraser
Michael Fraser
NHNicholas J Harding
Nicholas J Harding
RBRichard de Borja
Richard de Borja
Dominique TrudelDominique Trudel
Dominique Trudel
RBRobert G Bristow
Robert G Bristow

16 May 2016 in Nature Genetics
Verified
Journal Article
Closed access
AMAndrew William McPherson
Andrew William McPherson
ARAndrew Roth
Andrew Roth
ELEmma Laks
Emma Laks
TMTehmina Masud
Tehmina Masud
ABAli Bashashati
Ali Bashashati
SSSohrab P Shah
Sohrab P Shah

24 April 2017 in Nature Genetics
Verified
Journal Article
Closed access
YWYi Kan Wang
Yi Kan Wang
ABAli Bashashati
Ali Bashashati
MAMichael S. Anglesio
Michael S. Anglesio
DCDawn R Cochrane
Dawn R Cochrane
DGDiljot S Grewal
Diljot S Grewal
SSSohrab P Shah
Sohrab P Shah

13 December 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
RKRobert Kridel
Robert Kridel
FCFong Chun Chan
Fong Chun Chan
AMAnja Mottok
Anja Mottok
MBMerrill Boyle
Merrill Boyle
PFPedro Farinha
Pedro Farinha
SSSohrab P Shah
Sohrab P Shah
Follicular lymphoma (FL) is an indolent, yet incurable B cell malignancy. A subset of patients experience an increased mortality rate driven by two distinct clinical end points: histological transformation and early progression after immunochemotherapy. The nature of tumor clonal dynamics leading to these clinical end points is poorly understood, and previously determined genetic alterations do not explain the majority of transformed cases or accurately predict early progressive disease. We contend that detailed knowledge of the expansion patterns of specific cell populations plus their associated mutations would provide insight into therapeutic strategies and disease biology over the time course of FL clinical histories. Using a combination of whole genome sequencing, targeted deep sequencing, and digital droplet PCR on matched diagnostic and relapse specimens, we deciphered the constituent clonal populations in 15 transformation cases and 6 progression cases, and measured the change in clonal population abundance over time. We observed widely divergent patterns of clonal dynamics in transformed cases relative to progressed cases. Transformation specimens were generally composed of clones that were rare or absent in diagnostic specimens, consistent with dramatic clonal expansions that came to dominate the transformation specimens. This pattern was independent of time to transformation and treatment modality. By contrast, early progression specimens were composed of clones that were already present in the diagnostic specimens and exhibited only moderate clonal dynamics, even in the presence of immunochemotherapy. Analysis of somatic mutations impacting 94 genes was undertaken in an extension cohort consisting of 395 samples from 277 patients in order to decipher disrupted biology in the two clinical end points. We found 12 genes that were more commonly mutated in transformed samples than in the preceding FL tumors, including TP53, B2M, CCND3, GNA13, S1PR2, and P2RY8. Moreover, ten genes were more commonly mutated in diagnostic specimens of patients with early progression, including TP53, BTG1, MKI67, and XBP1. Our results illuminate contrasting modes of evolution shaping the clinical histories of transformation and progression. They have implications for interpretation of evolutionary dynamics in the context of treatment-induced selective pressures, and indicate that transformation and progression will require different clinical management strategies.

16 May 2016 in Nature Methods
Verified
Journal Article
Closed access
ARAndrew Roth
Andrew Roth
AMAndrew William McPherson
Andrew William McPherson
ELEmma Laks
Emma Laks
JBJustina Biele
Justina Biele
DYDamian Yap
Damian Yap
SSSohrab P Shah
Sohrab P Shah

6 September 2024 in Science
Verified
Journal Article
Closed access
LSLaksshman Sundaram
Laksshman Sundaram
AKArvind Kumar
Arvind Kumar
MZMatthew Zatzman
Matthew Zatzman
ASAdriana Salcedo
Adriana Salcedo
NRNeal Ravindra
Neal Ravindra
HSHui Shen
Hui Shen
To identify cancer-associated gene regulatory changes, we generated single-cell chromatin accessibility landscapes across eight tumor types as part of The Cancer Genome Atlas. Tumor chromatin accessibility is strongly influenced by copy number alterations that can be used to identify subclones, yet underlying cis-regulatory landscapes retain cancer type–specific features. Using organ-matched healthy tissues, we identified the “nearest healthy” cell types in diverse cancers, demonstrating that the chromatin signature of basal-like–subtype breast cancer is most similar to secretory-type luminal epithelial cells. Neural network models trained to learn regulatory programs in cancer revealed enrichment of model-prioritized somatic noncoding mutations near cancer-associated genes, suggesting that dispersed, nonrecurrent, noncoding mutations in cancer are functional. Overall, these data and interpretable gene regulatory models for cancer and healthy tissue provide a framework for understanding cancer-specific gene regulation.